Clinical trial NCT01077960: Safety and Efficacy Study of Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome
Official title: Phase III, Multi-Center, Open, 12-Week, Follow-up Safety and Efficacy Study of Serostim® in Subjects With Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome (HARS)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome
Keywords: Serostim
HARS
Lead sponsor: EMD Serono
Sponsor class: INDUSTRY
First posted: 2010-03-01
Enrollment: 126
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: In Serono Study 24380, the antecedent protocol to Study 25373, patients were randomly assigned in a 3.0-to-1.0 ratio to Groups A and B. All patients in Group A received recombinant human growth hormone (Serostim®) 4 mg daily (the "induction" phase) for the first 12 weeks, and then were re-randomized to receive either placebo or Serostim 2 mg on alternate days (roughly equivalent to 1 mg daily) during Weeks 12-36 (the "maintenance" phase). All patients in Group B initially received placebo from baseline to Week 24, and then received Serostim® 4 mg daily from Weeks 24 to 36 (Grunfeld, 2007).

In the follow-up Study 25373, any subject who was enrolled in Serono Study 24380 and was assigned to Group A, who fully completed all study visits without a major protocol violation, was eligible to enroll to receive re-treatment with Serostim at a dose of 4 mg daily for 12 weeks. During study 25373, safety was monitored by recording of adverse events and measurement of urinalysis and laboratory blood tests to assess fasting glucose, fasting insulin, and routine biochemistry and hematology parameters. At Week 12 or at the time of study termination, subjects underwent re-assessment of body composition via anthropometry measurements and dual photon absorptiometry (DXA) scanning. In addition, at study termination, measurements of insulin-like growth factor I (IGF-I), insulin-like growth binding protein 3 (IGFBP-3), fasting lipid profile, and oral glucose tolerance testing were obtained.


Eligibility criteria: Inclusion Criteria:

* Must meet all inclusion/exclusion criteria for Serono Study 25373, have participated in Serono Study 24380, must have been assigned to Group A, must have completed all treatments and procedures (including baseline, Week 12 and Week 36 Computerized Tomography (CT) and Dual-Energy X-ray Absorptiometry (DXA) Scans) and had no major protocol violation.
* Must be taking antiretroviral medications that are approved or are available under a Treatment Investigational New Drug (IND). Subjects must also agree not to discontinue or to change their regimen for the duration of the study except as judged medically necessary.
* Must be willing and able to comply with the protocol for the duration of the study.
* Must have voluntarily provided written informed consent and a subject authorization under Health Insurance Portability and Accountability Act of 1996 (HIPAA), prior to any study-related procedure that is not part of normal medical care, and with the understanding that the subject may withdraw consent at any time without prejudice to future medical care.
* If female, subjects must either:

  * Be post menopausal (=/\>1 year) or surgically sterilized (i.e., have undergone tubal ligation or hysterectomy), or
  * Use a contraceptive method for the duration of the study such as: hormonal contraceptive,intra uterine device,diaphragm with spermicide, or condom with spermicide, and
  * Must be neither pregnant nor breast feeding.
  * Confirmation that female subjects of childbearing potential are not pregnant must be established by a negative pregnancy test prior to initiating first treatment.

A pregnancy test is not required if the subject is post menopausal or surgically sterilized.

Exclusion Criteria:

* Have any condition, which interferes with informed consent or protocol compliance including, but not limited to, active substance abuse and/or dementia.
* Have any active malignancy, except localized cutaneous Kaposi's sarcoma (fewer than 10 lesions, none of which are larger than 2 cm, and not on active therapy).
* Have active central nervous system (CNS) process associated with neurological findings.
* Have acute illness treated in an intensive care unit, e.g., due to complications following open heart or abdominal surgery, multiple accidental trauma, or acute respiratory failure.
* Have any medical condition in view of which the study doctor and/or Serono Medical/Therapeutic Director feels that it would be in the best interest of the subject not to participate in the follow-up study.
* Are unable to comply with the Concomitant Therapy restrictions as outlined in Section 5.5 and listed as follows:

  * Therapy for obesity including therapy with anorexigenic or fat reducing drugs.
  * Anti-diabetic or insulin sensitizing medications.
  * Systemic glucocorticoids.
  * Systemic chemotherapy, interferon or radiation therapy treatment.
  * Androgenic agents including, but not limited to, testosterone, nandrolone (Deca-durabolin), oxandrolone (Oxandrin), oxymetholone (Anadrol), dehydroepiandrosterone (DHEA), etc. (Testosterone replacement therapy for hypogonadism is the exception to this exclusion and will be allowed if started \>30 days prior to Study Day 1 of Serono Study 24380).
  * Progestational agents, unless used for oral contraception or post-menopausal hormone replacement therapy.
  * Appetite stimulants such as dronabinol (Marinol), megestrol acetate (Megace), or cyproheptadine (Periactin).
  * Investigational agents, unless approved in advance by Serono's Medical Director. Specifically, experimental antiretroviral agents are disallowed, unless available under a treatment IND or expanded access program (30 days).
  * Liposuction or other elective plastic surgery.
  * Acquired Immune Deficiency Syndrome (AIDS) wasting therapy with growth hormone and/or prior treatment with growth hormone or a growth hormone releasing factor (for 12 months prior to the screening visit).
* Are participating in any other clinical studies (except Serono Study 24380). Observation studies are allowed, but prior written permission by Serono Medical/Therapeutic Director must be granted.

Primary outcomes:
measure: Change From Baseline to Week 12 in Trunk Fat as Assessed by Dual-Energy X-Ray Absorptiometry (DXA) Scan
timeFrame: baseline to 12 weeks
Secondary outcomes:
measure: Change From Baseline to Week 12 in Waist Circumference
timeFrame: baseline to 12 weeks
measure: Change From Baseline to Week 12 in Insulin-like Growth Factor I
timeFrame: baseline to 12 weeks
measure: Oral Glucose Tolerance Testing - Change From Baseline to Week 12 in Fasting Insulin
timeFrame: baseline to 12 weeks
measure: Oral Glucose Tolerance Testing - Change From Baseline to Week 12 in 120 Minute Glucose
timeFrame: baseline to 12 weeks
measure: Oral Glucose Tolerance Testing - Change From Baseline to Week 12 in Fasting Glucose
timeFrame: baseline to 12 weeks
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: University of Alabama/Birmingham
state: Alabama
city: Los Angeles
country: United States
facility: Care Clinic
state: California
city: Palm Beach
country: United States
facility: Private Practice
state: California
city: San Diego
country: United States
facility: UCSD - AVRC (AntiViralResearchCenter)
state: California
city: San Francisco
country: United States
facility: Kaiser Permanente
state: California
city: Torrence
country: United States
facility: Harbor-UCLA Medical Center
state: California
city: West Hollywood
country: United States
facility: AIDS Alliance
state: California
city: Norwalk
country: United States
facility: Circle Medical LLC
state: Connecticut
city: Washington
country: United States
facility: Private Practice
state: District of Columbia
city: Fort Lauderdale
country: United States
facility: Private Practice
state: Florida
city: Miami
country: United States
facility: Care Resources
state: Florida
city: Miami
country: United States
facility: Private Practice
state: Florida
city: North Miami Beach
country: United States
facility: Private Practice
state: Florida
city: Sarasota
country: United States
facility: Infectious Disease Associates
state: Florida
city: Atlanta
country: United States
facility: AIDS Research Consortium of Atlanta
state: Georgia
city: Chicago
country: United States
facility: Rush University Medical Center
state: Illinois
city: Boston
country: United States
facility: Community Research Initiative of New England
state: Massachusetts
city: Boston
country: United States
facility: Tufts University School of Medicine
state: Massachusetts
city: Minneapolis
country: United States
facility: Hennepin County Medical Center
state: Minnesota
city: New York
country: United States
facility: St. Luke's Roosevelt Hospital
state: New York
city: New York
country: United States
facility: St. Vincents Catholic Medical Center
state: New York
city: New York
country: United States
facility: Weill Medical College of Cornell University
state: New York
city: Austin
country: United States
facility: Central Texas Clinical Research
state: Texas
city: Annandale
country: United States
facility: IPD Research
state: Virginia
city: Spokane
country: United States
facility: Private Practice
state: Washington
city: Vancouver
country: Canada
facility: St Paul Hospital
state: British Columbia
Study officials:
References:
citation: Grunfeld C, Thompson M, Brown SJ, Richmond G, Lee D, Muurahainen N, Kotler DP; Study 24380 Investigators Group. Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy. J Acquir Immune Defic Syndr. 2007 Jul 1;45(3):286-97. doi: 10.1097/QAI.0b013e3180691145.